3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
29
Prostate Adenocarcinoma
3
Stage I Prostate Adenocarcinoma AJCC v7
1
PSA Level Greater Than Two
1
Neoplasms
1
Neoplasm Metastasis
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Adenocarcinoma
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
luprolide acetate gel depot
×
Clear all
NCT06855589
2025-03-04
PCS-XII
Charles LeMoyne Hospital
Phase 3
Not yet recruiting
400 enrolled